MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ
3.320
-0.100
-2.92%
Pre Market: 3.270 -0.05 -1.51% 08:53 12/05 EST
OPEN
3.410
PREV CLOSE
3.420
HIGH
3.430
LOW
3.300
VOLUME
3.81K
TURNOVER
0
52 WEEK HIGH
3.600
52 WEEK LOW
0.6666
MARKET CAP
768.43M
P/E (TTM)
-4.8312
1D
5D
1M
3M
1Y
5Y
1D
Gossamer Bio management to meet with Oppenheimer
TipRanks · 1d ago
Weekly Report: what happened at GOSS last week (1124-1128)?
Weekly Report · 4d ago
Gossamer Bio, Inc.'s (NASDAQ:GOSS) 28% Share Price Surge Not Quite Adding Up
Simply Wall St · 11/25 13:06
Gossamer Bio to Present at Piper Sandler Healthcare Conference
Reuters · 11/24 21:01
Weekly Report: what happened at GOSS last week (1117-1121)?
Weekly Report · 11/24 10:28
Gossamer Bio’s Seralutinib Advances: Buy Rating Backed by Promising Late-Stage Trials and Expansion
TipRanks · 11/19 01:35
Weekly Report: what happened at GOSS last week (1110-1114)?
Weekly Report · 11/17 10:29
Gossamer Bio price target raised to $12 from $9 at Oppenheimer
TipRanks · 11/10 13:36
More
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

Webull offers Gossamer Bio Inc stock information, including NASDAQ: GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.